News | September 17, 2010

German Company Reports First-in-Man Transcatheter Aortic Valve

September 17, 2010 - An aortic valve has been successfully implanted in the acute porcine model by Transcatheter Technologies GmbH (TT) using its Trinity system.

The acute in vivo study of the system has shown:

• Accurate stepwise positioning of Trinity via an antegrade transapical approach.
• Full expansion and anchoring of the Trinity valve prosthesis before the refolding of the stent.
• Complete evaluation of the fully expanded prosthesis’ function before refolding and repositioning or retrieval.
• Detachment of the stent from the catheter without changing the geometry of the deployed valve prosthesis.
• Outstanding anchoring and sealing due to the design of the stent.
• Low transvalvular gradients.

TT’s true repositioning system allows for complete expansion of the valved stent and full evaluation of prosthesis' function before repositioning, before retrieval and before final release.

“Trinity protects the fragile valve leaflets by Zero Pressure Crimping. This prevents crushing and damaging of the leaflets when the frame is folded. We expect that this will increase the lifespan of the valve prosthesis and thereby allow for implantation in even younger patients,” commented Wolfgang Goetz, M.D., Ph.D., CEO. “Our animal trials validate the feasibility of the technology in vivo. We are very proud to have achieved this significant milestone within a very short period of time.”

Transcatheter Technologies successfully closed the seed financing round in 2009 with High-Tech Gründerfonds and Seedfonds Bayern. The investment will be used for the development of a novel biological heart valve up to the proof of concept.

“Transcatheter Technologies’ valve design can solve major problems of common prosthesis. Thereby, valve implantations become an option for currently untreatable patients,” said Dr. Michael Nettersheim, of High-Tech Gründerfonds. “We are convinced that the medicinal as well as technological expertise of the team provide an ideal base for a successful corporate development.”

For more information: www.high-tech-gruenderfonds.de

Related Content

Mick Jagger Recovering After TAVR Procedure
News | Heart Valve Technology | April 08, 2019 | Jeff Zagoudis, Associate Editor
Rolling Stones frontman Mick Jagger is reportedly recovering after undergoing a transcatheter aortic valve valve...
 Evolut Low Risk Trial compared the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. The randomized trial, which met its primary non-inferiority endpoint of all-cause mortality or disabling stroke at two years compared to surgery (5.3 vs. 6.7 percent; posterior probability of non-inferiority >0.999), was presented at the American College of Cardiology (ACC) 2019 meeting
News | Heart Valve Technology | April 03, 2019
April 3, 2019 – The ACC.19 late-breaking landmark Evolut Low Risk Trial compared the minimally invasive Evolut transc
TAVR Outperforms Surgery in Younger, Low-Risk Aortic Stenosis Patients
News | Heart Valve Technology | March 22, 2019
Among patients with severe symptomatic aortic stenosis at low surgical risk, transcatheter aortic valve replacement (...
ACC Launches Transcatheter Valve Certification
News | Heart Valve Technology | March 14, 2019
March 14, 2019 — Beginning in mid-2019, hospitals performing...
FDA Approves MitraClip for Use in Heart Failure Patients With Functional Mitral Regurgitation
Feature | Heart Valve Technology | March 14, 2019 | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S.
Scientists Discover New Type of Immune Cells Essential for Forming Heart Valves

Microscopic images of a normal heart valve in a mouse, left, and a heart valve grown in a lab with heart-derived macrophages blocked, right. Without those macrophages, the valves are thick and deformed. Image courtesy of Developmental Cell/UCLA Broad Stem Cell Research Center.

News | Heart Valve Technology | March 06, 2019
UCLA researchers have identified for the first time the origin of an immune cell that plays a critical role in the...
Global Market for Transcatheter Treatments to Double in Next Five Years
News | Heart Valve Technology | March 01, 2019
When it comes to treatment options for a damaged heart valve, nothing is getting more attention than transcatheter...
Overlay Init